Champix: Clinically Proven Smoking Cessation Support
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 28 | $5.16 | $144.58 (0%) | 🛒 Add to cart |
| 56 | $4.48 | $289.16 $251.01 (13%) | 🛒 Add to cart |
| 84 | $4.17
Best per pill | $433.75 $350.41 (19%) | 🛒 Add to cart |
Synonyms | |||
Champix (varenicline) is a prescription medication specifically designed to aid smoking cessation by targeting nicotine receptors in the brain. It functions as a partial agonist, meaning it both reduces withdrawal symptoms and diminishes the pleasurable effects of smoking. This dual-action approach supports individuals in breaking the psychological and physical dependence on nicotine, making it a cornerstone in structured quit attempts under medical supervision.
Features
- Active ingredient: Varenicline (as varenicline tartrate)
- Available in 0.5 mg and 1 mg film-coated tablets
- Partial nicotinic acetylcholine receptor agonist
- 12-week standard treatment course, with option for additional 12 weeks in certain cases
- Requires prescription and medical oversight
Benefits
- Significantly increases long-term abstinence rates compared to placebo or unaided attempts
- Reduces severity of nicotine cravings and withdrawal symptoms
- Diminishes the satisfaction derived from smoking if a lapse occurs
- Supports behavioral change by addressing both physiological and psychological dependence
- Backed by extensive clinical trial data and real-world evidence
- May be used as part of a comprehensive cessation program including counseling
Common use
Champix is indicated for use in adults aged 18 and over as an aid to smoking cessation. Treatment should be initiated in motivated patients committed to abstaining from tobacco use, ideally with a target quit date set between days 8 and 14 of treatment. It is most effective when incorporated into a support program that includes behavioral counseling and regular follow-up with healthcare providers to monitor progress and address challenges.
Dosage and direction
Treatment follows a structured titration schedule to improve tolerability:
- Days 1–3: 0.5 mg once daily
- Days 4–7: 0.5 mg twice daily
- Day 8 to end of treatment: 1 mg twice daily
Patients should choose a target quit date between day 8 and day 14 of treatment. Tablets should be taken orally after food with a full glass of water to reduce potential nausea. The standard treatment duration is 12 weeks; for patients who have successfully stopped smoking, an additional 12-week course may be considered to maintain abstinence. Dosage adjustment is recommended in patients with severe renal impairment.
Precautions
Patients should be monitored for changes in behavior, hostility, agitation, depressed mood, and suicidal ideation, as neuropsychiatric adverse events have been reported. Use caution in patients with a history of psychiatric illness. Cardiovascular events have been observed in patients with cardiovascular disease; weigh benefits against risks. Nausea, the most common adverse effect, can often be managed by taking with food and adequate hydration. Not recommended during pregnancy or breastfeeding. May affect ability to drive or operate machinery.
Contraindications
Hypersensitivity to varenicline or any excipients. End-stage renal disease. Severe renal impairment requires dosage adjustment. Not recommended in patients under 18 years of age. Should not be used concurrently with other smoking cessation therapies unless specifically advised by a healthcare professional.
Possible side effects
Very common (≥1/10): nausea, insomnia, abnormal dreams Common (≥1/100 to <1/10): headache, drowsiness, dizziness, dysgeusia, increased appetite, vomiting, constipation, diarrhea, dyspepsia, abdominal pain, flatulence, dry mouth, fatigue, malaise Uncommon (≥1/1,000 to <1/100): depression, anxiety, irritability, restlessness, altered mood, agitation, aggression, emotional lability, tachycardia, hypertension, hypotension, flushing, rash, pruritus, hyperhidrosis, arthralgia, myalgia, chest pain, weight gain Rare but serious: suicidal ideation and behavior, seizures, hypersensitivity reactions, angioedema, erythema multiforme, Stevens-Johnson syndrome, acute coronary syndrome, cerebrovascular accident
Drug interaction
No clinically significant pharmacokinetic interactions with cimetidine, warfarin, transdermal nicotine, or bupropion. However, concomitant use with other smoking cessation therapies is not generally recommended. May potentiate effects of alcohol. Use caution with drugs that affect renal elimination. Theoretical potential for interaction with drugs that are actively secreted by renal tubular secretion (e.g., metformin).
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent receptor coverage.
Overdose
Cases of overdose have reported nausea, vomiting, drowsiness, tachycardia, and disorientation. Supportive care is recommended, including monitoring of vital signs and ECG. Due to renal elimination, dialysis may be effective in severe cases. Contact poison control center or seek immediate medical attention for appropriate management.
Storage
Store below 30°C (86°F) in original packaging to protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual results may vary based on health status, adherence to treatment, and other factors.
Reviews
Clinical trials demonstrate approximately 44% continuous abstinence rates at weeks 9–12 with Champix compared to 18% with placebo. Real-world evidence supports effectiveness, though individual experiences vary. Many patients report significantly reduced cravings and increased quit success when used as directed with behavioral support. Some users report side effects, particularly nausea, though this often diminishes over time. Healthcare providers generally regard Champix as an effective option within comprehensive cessation programs.